Track topics on Twitter Track topics that are important to you
Teva Present Long Term Data Efficacy Safety Fremanezumab PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Teva Present Long Term Data Efficacy Safety Fremanezumab articles that have been published worldwide.
We have published hundreds of Teva Present Long Term Data Efficacy Safety Fremanezumab news stories on BioPortfolio along with dozens of Teva Present Long Term Data Efficacy Safety Fremanezumab Clinical Trials and PubMed Articles about Teva Present Long Term Data Efficacy Safety Fremanezumab for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Teva Present Long Term Data Efficacy Safety Fremanezumab Companies in our database. You can also find out about relevant Teva Present Long Term Data Efficacy Safety Fremanezumab Drugs and Medications on this site too.
Treatment with botulinum toxin A is the evidence-based first-line therapy of cervical dystonia. The aim of this study was to analyze long-term data of the most commonly used products concerning safety and efficacy in a big cohort over decades.
Clomiphene citrate (CC) may be used as an off-label treatment for hypogonadism. There is little long-term data on the efficacy and safety of CC when administered for over three years. We aimed to assess improvements in testosterone and hypogonadal symptoms while on CC for extended periods of time.
Since the registration of Maraviroc (MVC) as antiretroviral agent in 2008, only studies with a follow-up time shorter than five years were published. Therefore, little is known about its long-term safety and efficiency in clinical practice. In this cohort study, data on long-term follow-up of MVC-treatment in routine practice was analysed.
Many patients with Cushing's disease (CD) require chronic pharmacotherapy to control their hypercortisolism, necessitating a comprehensive understanding of the long-term efficacy and safety of available therapies.
To address the need for long-term lasmiditan data, the GLADIATOR study evaluated the safety (primary) and efficacy (secondary) of lasmiditan for the intermittent, acute treatment of migraine attacks for up to 1 year.
Final data are presented for the ORAL Sequel long-term extension (LTE) study evaluating the safety and efficacy of tofacitinib 5 mg and 10 mg twice daily (BID) for up to 9.5 years in patients with rheumatoid arthritis (RA).
To investigate the long-term safety and efficacy of weekly subcutaneous IgPro20 (Hizentra, CSL Behring) in chronic inflammatory demyelinating polyneuropathy (CIDP).
Glycerol phenylbutyrate (GPB) is currently approved for use in the US and Europe for patients of all ages with urea cycle disorders (UCD) who cannot be managed with protein restriction and/or amino acid supplementation alone. Currently available data on GPB is limited to 12 months exposure. Here, we present long-term experience with GPB.
Several foreign studies have shown long-term efficacy of sublingual immunotherapy (SLIT), but data on the long-term efficacy of SLIT in China are still lacking.
To evaluate the long-term drug retention, efficacy, and safety of the infliximab biosimilar CT-P13 in Korean patients with ankylosing spondylitis (AS) in clinical practice. The primary outcome was drug retention (i.e. time to treatment discontinuation or changing to another biologic) in Korean patients with AS. Additional outcomes included efficacy and safety.
Short-term studies have shown that bempedoic acid, an inhibitor of ATP citrate lyase, reduces levels of low-density lipoprotein (LDL) cholesterol. Data are limited regarding the safety and efficacy of bempedoic acid treatment in long-term studies involving patients with hypercholesterolemia who are receiving guideline-recommended statin therapy.
P1093 is an ongoing phase I/II multicenter open-label study of dolutegravir plus an optimized background regimen in age-defined pediatric cohorts; here we report the long-term safety and virologic efficacy outcomes for the oldest cohort.
Osteoporosis is a major complication in patients with primary biliary cholangitis (PBC) and autoimmune hepatitis (AIH). Denosumab, a fully human monoclonal antibody against the receptor activator of nuclear factor-κB ligand (RANKL), increases bone mineral density (BMD) by inhibiting development and activity of osteoclasts and decreasing bone resorption. We have already reported the efficacy and safety of short-term (1-year) denosumab therapy for osteoporosis in patients with PBC or AIH (1), but the effect ...
The minimally invasive ab-interno trabeculectomy (AIT) via electro-ablation with the Trabectome has been on the European market since 2009. Many studies have proven the safety and efficacy of the procedure. Up until now, studies investigating the long-term effect of AIT have been sparse. In this study, we present long-term results of AIT in patients with primary and secondary open-angle glaucoma.
The aim of the study is to evaluate the long-term efficacy and safety of Vedolizumab in a real-life cohort of IBD patients enrolled at a tertiary referral center.
Molidustat, a novel hypoxia-inducible factor-prolyl hydroxylase inhibitor, is being investigated for the treatment of anemia associated with chronic kidney disease (CKD). The efficacy and safety of molidustat were recently evaluated in three 16-week phase 2b studies. Here, we report the results of two long-term extension studies of molidustat.
To assess the long-term safety and efficacy of eslicarbazepine acetate (ESL) monotherapy in adults with focal seizures (FS).
A promising new gene technology has been developed for the treatment of osteoarthritis, utilizing transduced human cells expressing transforming growth factor-β1. The safety and efficacy of this treatment modality has been demonstrated in laboratory studies, as well as Phase I, II, and current Phase III human clinical trials. Due to a misidentification error, there have been concerns that this cell-based gene therapy is based on a different cell than the one that was initially approved. However, its safety...
Long-term treatment is recommended in major depressive disorder (MDD) to prevent relapse and to restore functioning. The aim of this study (Orion; NCT01360866) was to assess the long-term safety, tolerability, and efficacy of open-label treatment with adjunctive brexpiprazole in adult patients with MDD.
Cellulite is a common female cosmetic concern for which there are few treatment options with long-term effectiveness data. The aim of this multisite prospective registry study was to collect observational data on the real-life clinical use of a tissue stabilized-guided subcision (TS-GS) system for long-term improvement of cellulite appearance.
Efficacy and safety of long-term baricitinib with and without methotrexate for the treatment of rheumatoid arthritis: experience with baricitinib monotherapy continuation or after switching from methotrexate monotherapy or baricitinib plus methotrexate.
To evaluate the long-term efficacy and safety of maintaining baricitinib monotherapy in patients with active rheumatoid arthritis (RA) originally treated with baricitinib monotherapy or switched from methotrexate (MTX) or the combination of baricitinib plus MTX to baricitinib monotherapy.
Several single center short-term studies have demonstrated the feasibility, safety and positive clinical outcomes of Permanent His bundle pacing (HBP). We performed a retrospective study to evaluate long-term technical and safety performances of HBP in a large population of pacemaker patients from two different centers.
Long-term data on enzyme replacement treatment of hypophosphatasia (HPP) are limited.
Miltefosine (MF) is the only oral drug available for treatment of visceral leishmaniasis (VL) and post-kala-azar dermal leishmaniasis (PKDL). Although the drug is effective and well tolerated in treatment of VL, the efficacy and safety of MF for longer treatment durations (>28 days) in PKDL remains unclear. This study provides an overview of the current knowledge about safety and efficacy of long treatment courses with MF in PKDL, as a strategy in the VL elimination in South Asia.